Results 1 to 10 of about 1,138 (104)
A Novel Immunocytokine Promotes T Cell– and Cytokine-Induced Killer Cell-Mediated Antitumor Immunity via a Non-MHC-Restricted Mechanism in Glioblastoma [PDF]
Journal of Translational MedicineBackground Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumor in adults, characterized by an immunosuppressive microenvironment. To address the immune desert in GBM, immunocytokine, an innovative recombinant fusion protein
Liangxue Zhou, Mingbin Bao, Huaqing Lü
exaly +3 more sources
OncoImmunology, 2021 Targeted immunotherapy of solid cancers with chimeric antigen receptor (CAR) T cells and immunocytokines are attractive options in that they both rely on the specificity of tumor-targeted antibodies.
John E Shively +2 more
exaly +2 more sources
Miniaturized IL-2/anti-IL-2 immunocytokines selectively activate and support the in vivo persistence of regulatory T cells [PDF]
Frontiers in ImmunologyIntroductionInterleukin-2 (IL-2) is a multifunctional cytokine that potently expands regulatory T cells (Tregs) and thus has potential in mitigating autoimmune diseases and promoting transplant tolerance.
Charina S. Fabilane +24 more
doaj +2 more sources
Improved Intratumoral Penetration of IL12 Immunocytokine Enhances the Antitumor Efficacy
Frontiers in Immunology, 2022 Tumor-targeting antibody (Ab)-fused cytokines, referred to as immunocytokines, are designed to increase antitumor efficacy and reduce toxicity through the tumor-directed delivery of cytokines.
Wook Kim, Yong-Sung Kim, Keunok Jung
exaly +3 more sources
MAbs, 2021 Simlukafusp alfa (FAP-IL2v, RO6874281/RG7461) is an immunocytokine comprising an antibody against fibroblast activation protein α (FAP) and an IL-2 variant with a retained affinity for IL-2Rβγ > IL-2 Rβγ and abolished binding to IL-2 Rα.
Otto C. Boerman +2 more
exaly +3 more sources
Frontiers in Immunology, 2022 IntroductionThe anti-CD20 antibody rituximab (RTX) has substantially improved outcomes of patients with B-cell lymphomas, although more efficient therapies are needed for refractory or relapsing lymphomas.
Tays Hernández
exaly +3 more sources
OncoImmunology, 2020 While anti-CEA antibodies have no direct effect on CEA-positive tumors, they can be used to direct potent anti-tumor effects as an antibody-IL-2 fusion protein (immunocytokine, ICK), and at the same time reduce the toxicity of IL-2 as a single agent ...
Susanta K Hui +2 more
exaly +2 more sources
A New Antibody–Cytokine Construct Targeting Natural Killer Cells: An Immunotherapeutic Approach to Chronic Lymphocytic Leukemia [PDF]
BiomoleculesIn chronic lymphocytic leukemia (CLL), natural killer (NK) cells show a dysfunctional phenotype that correlates with disease progression. Our aim was to restore NK cell functionality in CLL through a specifically targeted IL15-stimulating activity; IL15 ...
Michela Flego +12 more
doaj +2 more sources
OncoImmunology, 2017 We developed cergutuzumab amunaleukin (CEA-IL2v, RG7813), a novel monomeric CEA-targeted immunocytokine, that comprises a single IL-2 variant (IL2v) moiety with abolished CD25 binding, fused to the C-terminus of a high affinity, bivalent carcinoembryonic
Anne Freimoser-Grundschober +2 more
exaly +2 more sources
A novel nanobody-based immunocytokine of a mutant interleukin-2 as a potential cancer therapeutic [PDF]
AMB ExpressThe immunotherapeutic application of interleukin-2 (IL-2) in cancer treatment is limited by its off-target effects on different cell populations and insufficient activation of anti-tumor effector cells at the site of the tumor upon tolerated doses ...
Arezoo Beig Parikhani +9 more
doaj +2 more sources